Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
Boehringer and AimedBio partner to develop novel antibody-drug conjugate therapy aiming to transform the treatment landscape for a broad range of cancers.
-
Ingelheim, Germany / Ridgefield, Conn., U.S., April 28, 2025New data from the Phase Ib Beamion LUNG-1 trial were presented at AACR and simultaneously published in The New England Journal of...
-
Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers
-
CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s aim of transforming the lives of people with...
-
Inauguration of Angelika Amon research building in Vienna Sustainable research building at a cost of EUR 60 million offers modern office and laboratory spaceOver the past five years, Boehringer’s...
-
VANCOUVER, British Columbia, Dec. 16, 2020 (GLOBE NEWSWIRE) -- TRIUMF, Canada’s particle accelerator centre, today announced it has entered into a collaboration agreement with Fusion Pharmaceuticals...